Scientists from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.
Memorial Sloan Kettering Cancer Center announces the appointments of medical oncologist Anas Younes, surgical pathologist David S. Kimstra, surgeon Julio Garcia-Aguilar, and radiologist Wolfgang Weber.
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.
Westchester Medical Center today announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with Memorial Sloan Kettering Cancer Center, whose staff will provide outpatient cancer care and infusion services.
IBM, WellPoint, Inc., and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.
A new pancreatic cancer research center has been created at Memorial Sloan Kettering Cancer Center (MSKCC). The ambitious initiative was established with an initial commitment of $10 million from MSKCC Board member David M. Rubenstein.
Prostate cancer patients who are prescribed oral erectile medication before and after radiation therapy have improved sexual function, according to a research team at Memorial Sloan Kettering Cancer Center.